Clinical course of idiopathic inflammatory myopathies in the COVID-19 pandemic: a single-center experience

Apaydin H., Erden A., Güven S. C., Armağan B., Karakaş Ö., Özdemir B., ...Daha Fazla

Future Virology, cilt.17, sa.8, ss.545-556, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 8
  • Basım Tarihi: 2022
  • Doi Numarası: 10.2217/fvl-2021-0146
  • Dergi Adı: Future Virology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, Chemical Abstracts Core, EMBASE
  • Sayfa Sayıları: ss.545-556
  • Anahtar Kelimeler: corticosteroids, hydroxychloroquine, idiopathic inflammatory myopathies, immunosuppression, myositis, SARS-CoV-2
  • Gazi Üniversitesi Adresli: Hayır

Özet

© 2022 Future Medicine Ltd.Aim: To evaluate the clinical course of idiopathic inflammatory myopathy (IIM) patients in COVID-19 pandemic, and to assess the COVID-19 outcomes in infected IIM patients. Materials & methods: In this study, 39 patients were evaluated retrospectively. Myositis disease activity, myositis damage index, depression, fatigue, active medical treatment, drug compliance and SARS-CoV-2 PCR test results in COVID-19 pandemic were collected. Results: Fourteen of these patients (35%) were detected to have a positive SARS-CoV-2 PCR test. The demographic and clinical characteristics, active medical treatment, disease activity, depression and fatigue of the patients who had undergone or not SARS-CoV-2 were similar. Conclusion: Our results have shown that although prevalence of COVID-19 seems to be increased in IIM patients under immunosuppressive treatment, hospitalization rates were lower and no intensive care unit admissions or deaths were observed.